Ranbaxy Ltd will launch at least three copies of biotech medicines in India by 2015, mostly to treat cancer, and needs to develop such high-tech drugs to remain a serious player in the global generics business, CEO Arun Sawhney said on Tuesday.
Sawhney told Reuters that Ranbaxy, majority-owned by Japanese drugmaker Daiichi Sankyo, will introduce a biosimilar cancer treatment in India next year and follow up with at least two other biosimilars in the same market over the following year or two.
The company’s goal is to seek initial approval for all the drugs in India and then seek approval within four to five years in Europe and the United States.
Like biotech medicines, biosimilar drugs are made in living cells through a costly and time-consuming process. Ranbaxy currently sells only one biosimilar, a copycat form of Amgen Inc’s Neupogen, used to prevent infections following chemotherapy. The Ranbaxy product is sold in India.
Sawhney said two of Ranbaxy’s chief rivals, Israeli drugmaker Teva Pharmaceutical Industries and the Sandoz unit of Swiss drugmaker Novartis, already have expertise in biosimilars. Ranbaxy hopes to eventually compete with them in the potentially lucrative business, he said.
Sawhney, in an interview in New York, said his company plans to introduce a biosimilar cancer drug in India next year and that the medicine has the potential for global annual sales in the hundreds of millions of dollars.
“The attractiveness of biosimilars, regardless of the product, is you’ll always have limited competition because of the complexity and the investments required” to make such medicines, he said.
Other drugmakers, including Merck & Co, are racing to develop biosimilars even though the U.S. Food and Drug Administration has not yet announced formal guidelines for how biosimilar medicines should be tested and marketed. Europe has already released such guidelines.
“Of the top 10 drugs in the world, more than half are biotech drugs and probably seven of the top 10 will be by 2015. That tells us the importance of being present in the biosimilar space,” Sawhney said. “If we want to remain a serious (industry) player, inherently we must be competitive.”
Source: The Economic Times